Modulation of glucagon-like peptide-1 release by berberine: In vivo and in vitro studies

Biochemical Pharmacology

Volumn 79, Issue 7, 2010, Pages 1000-1006

  Yu, Yunli ^a   Liu, Li ^a   Wang, Xinting ^a   Liu, Xiang ^a   Liu, Xiaodong ^a   Xie, Lin ^a   Wang, Guangji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Berberine; Glucagon like peptide 1; Proglucagon; Prohormone convertase 3; Protein kinase C dependent pathway

Indexed keywords

BERBERINE; CHELERYTHRINE; COMPOUND C; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; INSULIN; MESSENGER RNA; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PROGLUCAGON; PROPROTEIN CONVERTASE 1; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GLUCOSE TOLERANCE TEST; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INTESTINE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; ANIMAL; BLOOD; BODY WEIGHT; CELL CULTURE; EATING; GENETICS; GLUCOSE BLOOD LEVEL; SECRETION; SPRAGUE DAWLEY RAT;

ANIMALS; BERBERINE; BLOOD GLUCOSE; BODY WEIGHT; CELLS, CULTURED; EATING; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; MALE; PROGLUCAGON; PROPROTEIN CONVERTASE 1; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 77449089475     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.11.017     Document Type: Article

References (31)

1. Rouille Y, Martin S, Steiner DF. Differential processing of proglucagon by the subtillisin-like prohormone convertase PC2 and PC3 to generate either glucagon or glucagon-like peptide. J Biol Chem 1995;270:26488-96.
2. Ranganath LR. Incretins: Pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. J Clin Pathol 2008;61:401-9. (Pubitemid 351518219)
3. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008;57:712-7. (Pubitemid 351608234)
4. Cheng Z, Pang T, Gu M, Gao AH, Xie CM, Li JY, et al. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim Biophys Acta 2006;1760:1682-9. (Pubitemid 44667275)
5. Tang LQ, Wei W, Chen LM, Liu S. Effects of berberine on diabetic induced by alloxan and a high-fat/high-cholesterol diet in rats. J Ethnopharmacol 2006;108:109-15. (Pubitemid 44498992)
6. Ko BS, Choi SB, Park SK, Jang JS, Kim YE, Park S. Insulin sensitizing and insulinotropic action of berberine from Cortidis Rhizoma. Biol Pharm Bull 2005;28:1431-7. (Pubitemid 41379694)
7. Yu YL, Lu SS, Yu S, Liu YC, Wang P, Xie L, et al. Huang-Lian-Jie-Du decoction modulates glucagon-like peptide 1 secretion in diabetic rats. J Ethnopharmacol 2009;124:444-9.
8. Lu SS, Yu YL, Zhu HJ, Liu XD, Liu L, Liu YW, et al. Berberine promotes glucagonlike peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats. J Endocrinol 2009;200:159-65.
9. de Bruïne AP, Dinjens WN, Pijls MM, vd Linden EP, Rousch MJ, Moerkerk PT, et al. NCI-H716 cells as a model for endocrine differentiation in colorectal cancer. Virchows Arch B Cell Pathol Incl Mol Pathol 1992;62:311-20.
10. Park JG, Frucht H, LaRocca RV, Bliss Jr DP, Kurita Y, Chen TR, et al. Characteristics of cell lines established from human colorectal cancer. Caner Res 1990;50:2773-80.
11. de Bruïne AP, Dinjens WN, van der Linden EP, Pijls MM, Moerkerk PT, Bosman FT. Extracellular matrix components induce endocrine differentiation in vitro in NCI-H716 cells. Am J Pathol 1993;142:773-82. (Pubitemid 24063995)
12. Anini Y, Brubaker PL. Muscarinic receptors control glucagon-Like Peptide 1 secretion by human endocrine L cells. Endocrinology 2003;144:3244-50. (Pubitemid 36819927)
13. Anini Y, Brubaker PL. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 2003;52:252-9. (Pubitemid 36173176)
14. Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide- induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 2009;58:1058-66.
15. Reimer RA, Darimont C, Gremlich S, Nicolas-Métral V, Rüegg UT, MacéK. A human cellular model for studying the regulation of glucagon-like peptide-1 secretion. Endocrinology 2001;142:4522-8. (Pubitemid 32907084)
16. Lim GE, Brubaker PL. Glucagon-like peptide 1 secretion by the L-cell the view from within. Diabetes 2006;55:S70-7. (Pubitemid 44927035)
17. Steensma A, Faassen-Peters MA, Noteborn HP, Rietjens IM. Bioavailability of genistein and its glycoside genistin as measured in the portal vein of freely moving unanesthetized rats. J Agric Food Chem 2006;54:8006-12. (Pubitemid 44785377)
18. Zhou L, Wang X, Shao L, Yang Y, Shang W, Yuan G, et al. Berberine acutely inhibits insulin secretion from beta-cells through 30,50-cyclic adenosine 50- monophosphate signaling pathway. Endocrinology 2008;149:4510-8.
19. Cole SP. Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother Pharmacol 1986;17:259-63. (Pubitemid 16070936)
20. Cani PD, Daubioul CA, Reusens B, Remacle C, Catillon G, Delzenne NM. Involvement of endogenous glucagons-like peptide-1 (7-36) amide on glycaemia- lowering effect of oligofructose in streptozotocin-treated rats. J Endocrinol 2005;185:457-65. (Pubitemid 40883391)
21. Orskov C, Poulsen SS, Moller M, Holst JJ. Glucagon-like peptide-1 receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptid-1. Diabetes 1996;45:832-5. (Pubitemid 26168585)
22. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-39. (Pubitemid 350041474)
23. Iakoubov R, Izzo A, Yeung A,Whiteside CI, Brubaker PL. Protein kinase Czeta is required for oleic acid-induced secretion of glucagon-like peptide-1 by intestinal endocrine L cells. Endocrinology 2007;148:1089-98.
24. Kong WJ, Zhang H, Song DQ, Xue R, Zhao W, Wei J, et al. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism 2009;58:109-19.
25. Lin TH, Kuo HC, Chou FP, Lu FJ. Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide. BMC Cancer 2008;8:58.
26. Brubaker PL, Schloos J, Drucker DJ. Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. Endocrinology 1998;139:4108-14. (Pubitemid 28513695)
27. Brubaker PL. Control of glucagon-like immunoreactive peptide secretion from fetal rat intestinal cultures. Endocrinology 1988;123:220-6.
28. Ong WK, Gribble FM, Reimann F, Lynch MJ, Houslay MD, Baillie GS, et al. The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release. Br J Pharmacol 2009;157:633-44.
29. Lochner A, Moolman JA. The many faces of H89: A review. Cardiovasc Drug Rev 2006;24:261-74. (Pubitemid 46435008)
30. Lee YS, KimWS, KimKH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006;55:2256-64. (Pubitemid 44743622)
31. Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H, et al. Berberine, and its more biologically available derivative dihydroberberine, inhibit mitochondrial respiratory complex I: A mechanism for the action of berberine to activate AMPK and improve insulin action. Diabetes 2008;57:1414-8.